Today: 7 February 2026
Subscribe
Browse Category

Healthcare Stocks News 22 January 2026 - 5 February 2026

Boston Scientific stock rebounds after brutal selloff — what Wall Street watches next

Boston Scientific stock rebounds after brutal selloff — what Wall Street watches next

Boston Scientific shares rebounded 3.3% Thursday to $77.97 after plunging 17% Wednesday, their steepest one-day drop in over 25 years, following a sales miss in the electrophysiology unit. The company reported Q4 net sales of $5.29 billion and forecast 2026 adjusted earnings of $3.43–$3.49 per share with 10–11% organic sales growth.
5 February 2026
·····
Intuitive Surgical stock price steadies near $480 as ISRG weathers Wall Street jitters

Intuitive Surgical stock price steadies near $480 as ISRG weathers Wall Street jitters

Intuitive Surgical shares rose 0.2% to $480.02 Wednesday afternoon after a volatile session, rebounding slightly from a two-day slide. The Nasdaq-tracking QQQ fell 1.6%, while the iShares U.S. Medical Devices ETF dropped 1%. Medtronic declined as Stryker gained. Trading volume in Intuitive surged to 3.8 million shares, more than double its 50-day average.
4 February 2026
····
Why Johnson & Johnson stock is up today: new Varipulse Plus update puts AFib data back in play

Why Johnson & Johnson stock is up today: new Varipulse Plus update puts AFib data back in play

Johnson & Johnson shares rose about 1.4% to $233.87 Tuesday after unveiling new pulsed-field ablation and imaging technologies ahead of the AF Symposium. The company will present Omny-AF pilot data on Feb. 6 and its stock will trade ex-dividend on Feb. 24. Medtronic announced a $585 million CathWorks acquisition as PFA competition intensifies.
3 February 2026
·····
Establishment Labs (ESTA) stock price jumps nearly 6% as Motiva sales and FDA filing stay in focus

Establishment Labs (ESTA) stock price jumps nearly 6% as Motiva sales and FDA filing stay in focus

Establishment Labs shares rose 5.7% to $72.02 in Monday afternoon trading after hitting $73.77. The company forecasted 2025 revenue between $210.5 million and $211.5 million, with a February earnings call set for full results. FDA review of Motiva implants for breast reconstruction is pending. The stock is up about 11% since Jan. 27.
2 February 2026
·····
Abbott Laboratories stock price: ABT ends Friday up 3% — what investors watch next week

Abbott Laboratories stock price: ABT ends Friday up 3% — what investors watch next week

Abbott Laboratories shares closed up 3% at $109.30 Friday after trading between $105.72 and $109.47. CEO Robert B. Ford bought 18,800 shares on January 23 for about $2 million. The company forecast 2026 organic sales growth of 6.5%–7.5% and reaffirmed plans to acquire Exact Sciences in Q2. Abbott’s Q1 earnings and nutrition outlook remain under pressure after missing revenue estimates.
31 January 2026
·····
Abbott stock rebounds as Exact Sciences vote nears after broker upgrade

Abbott stock rebounds as Exact Sciences vote nears after broker upgrade

Abbott Laboratories shares rose 2.6% to $108.89 Friday after missing revenue targets and guiding first-quarter adjusted EPS below analyst estimates. Freedom Capital Markets upgraded the stock to “buy” but cut its price target. Abbott expects to close its $23 billion Exact Sciences acquisition by Q2 2026. Exact Sciences shareholders will vote on the merger Feb. 20.
30 January 2026
·····
Abbott stock price today: ABT slips as CEO buy hits SEC filing after volatile week

Abbott stock price today: ABT slips as CEO buy hits SEC filing after volatile week

Abbott Laboratories shares fell 1.2% to $107.49 by midday Tuesday after CEO Robert Ford disclosed buying 18,800 shares at an average price of $107.13. The drop followed a weak quarterly outlook and missed revenue targets, with investors watching ongoing challenges in Abbott’s nutrition segment. Health-care stocks broadly declined after a proposed near-flat Medicare Advantage payment rate for 2027.
27 January 2026
·····
Dow Jones futures slip as UnitedHealth tumbles on Medicare rates, Fed and earnings loom

Dow Jones futures slip as UnitedHealth tumbles on Medicare rates, Fed and earnings loom

Dow futures fell 40 points premarket Tuesday as UnitedHealth dropped 8.6% after a proposed Medicare Advantage rate increase came in far below expectations. S&P 500 and Nasdaq futures rose ahead of major earnings reports and the start of the Federal Reserve meeting. Salesforce gained 2.2% after landing a $5.6 billion U.S. Army contract. A partial government shutdown loomed with funding set to expire after midnight Friday.
27 January 2026
······
Boston Scientific (BSX) stock ticks higher again — what to watch before Tuesday’s trade

Boston Scientific (BSX) stock ticks higher again — what to watch before Tuesday’s trade

Boston Scientific shares rose 1.12% to $93.55 Monday, outperforming Medtronic but lagging Abbott and Stryker. The company faces FDA scrutiny over its AXIOS GI stent after reports of injuries and deaths. Investors are focused on the $14.5 billion Penumbra acquisition, expected to close in 2026. Quarterly results are due Feb. 4.
27 January 2026
·····
Abbott Laboratories stock faces a Monday test as ABT hovers near a 52-week low

Abbott Laboratories stock faces a Monday test as ABT hovers near a 52-week low

Abbott shares fell 10.04% Thursday, their sharpest drop since 2002, closing Friday at $107.42. Analysts cut price targets after the company reported Q4 adjusted EPS of $1.50 and warned of weak nutrition sales for “a couple quarters.” Volume spiked to 37.1 million shares. The company expects full-year 2026 adjusted EPS of $5.55 to $5.80 and plans to close its Exact Sciences acquisition in Q2.
25 January 2026
····
Intuitive Surgical stock price dips as 2026 da Vinci outlook cools after Q4 beat (ISRG)

Intuitive Surgical stock price dips as 2026 da Vinci outlook cools after Q4 beat (ISRG)

Intuitive Surgical shares fell 0.2% to $524.65 after the company forecast slower da Vinci procedure growth of 13–15% for 2026, down from 18% in 2025. Fourth-quarter revenue rose 19% to $2.87 billion, with adjusted profit topping estimates. Management cited tariff risks and rising competition as headwinds. The company installed 532 da Vinci systems in Q4, bringing its total to 11,106.
23 January 2026
·····
PAVmed stock dips premarket after VA contract drives near-double rally in PAVM shares

PAVmed stock dips premarket after VA contract drives near-double rally in PAVM shares

PAVmed shares dropped 3.4% to $11.64 in premarket trading Thursday, following a 94.7% surge the previous session after its Lucid Diagnostics unit secured a U.S. Veterans Affairs contract for the EsoGuard test. Lucid shares fell 10.6% premarket. Investors are seeking details on test rollout and volumes. PAVmed recently completed a 1-for-30 reverse stock split to meet Nasdaq requirements.
22 January 2026
····
1 2 3 … 6

Stock Market Today

CapitaLand Investment share price jumps as CapitaLand REIT payouts roll in — what’s next for 9CI

CapitaLand Investment share price jumps as CapitaLand REIT payouts roll in — what’s next for 9CI

7 February 2026
CapitaLand Investment shares rose 1.3% to S$3.12 on Friday, bucking a 0.8% drop in Singapore’s benchmark index. CapitaLand Integrated Commercial Trust reported a 16.4% jump in second-half distributable income, while CapitaLand Ascendas REIT posted a 1.4% full-year rise. CapitaLand China Trust saw full-year DPU fall to 4.82 cents amid weaker yuan and occupancy. CLI reports FY2025 results on Feb. 11.
Go toTop